Adult bronchiolitis medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 8: | Line 8: | ||
==Medical Therapy== | ==Medical Therapy== | ||
*The optimal medical therapy for adult bronchiolitis is unknown.<ref name="pmid15805698">{{cite journal |vauthors=Azuma A, Kudoh S |title=Securing the safety and efficacy of macrolide therapy for chronic small airway diseases |journal=Intern. Med. |volume=44 |issue=3 |pages=167–8 |date=March 2005 |pmid=15805698 |doi= |url=}}</ref><ref name="pmid19210653">{{cite journal |vauthors=Parambil JG, Yi ES, Ryu JH |title=Obstructive bronchiolar disease identified by CT in the non-transplant population: analysis of 29 consecutive cases |journal=Respirology |volume=14 |issue=3 |pages=443–8 |date=April 2009 |pmid=19210653 |doi=10.1111/j.1440-1843.2008.01445.x |url=}}</ref><ref name="pmid15332401">{{cite journal |vauthors=Akpinar-Elci M, Travis WD, Lynch DA, Kreiss K |title=Bronchiolitis obliterans syndrome in popcorn production plant workers |journal=Eur. Respir. J. |volume=24 |issue=2 |pages=298–302 |date=August 2004 |pmid=15332401 |doi= |url=}}</ref> | *The optimal medical therapy for adult bronchiolitis is unknown.<ref name="pmid15805698">{{cite journal |vauthors=Azuma A, Kudoh S |title=Securing the safety and efficacy of macrolide therapy for chronic small airway diseases |journal=Intern. Med. |volume=44 |issue=3 |pages=167–8 |date=March 2005 |pmid=15805698 |doi= |url=}}</ref><ref name="pmid19210653">{{cite journal |vauthors=Parambil JG, Yi ES, Ryu JH |title=Obstructive bronchiolar disease identified by CT in the non-transplant population: analysis of 29 consecutive cases |journal=Respirology |volume=14 |issue=3 |pages=443–8 |date=April 2009 |pmid=19210653 |doi=10.1111/j.1440-1843.2008.01445.x |url=}}</ref><ref name="pmid15332401">{{cite journal |vauthors=Akpinar-Elci M, Travis WD, Lynch DA, Kreiss K |title=Bronchiolitis obliterans syndrome in popcorn production plant workers |journal=Eur. Respir. J. |volume=24 |issue=2 |pages=298–302 |date=August 2004 |pmid=15332401 |doi= |url=}}</ref> | ||
*Therapy is mainly the cessation of exposure to irritant agent. | *Therapy is mainly the cessation of exposure to irritant agent. | ||
*Bronchiolitis is treated based on severity, however, the disease is progressive and inevitably, leads to respiratory failure. | *Bronchiolitis is treated based on severity, however, the disease is progressive and inevitably, leads to respiratory failure. | ||
Line 14: | Line 14: | ||
*Bronchodilators and glucocorticoids have been heavily criticized in their role of improving symptoms, and are reserved only in those who show clinical improvement. | *Bronchodilators and glucocorticoids have been heavily criticized in their role of improving symptoms, and are reserved only in those who show clinical improvement. | ||
=== Adult bronchiolitis === | |||
===Adult bronchiolitis=== | |||
* '''1 Stage 1 - Respiratory compromise''' | * '''1 Stage 1 - Respiratory compromise''' | ||
** 1.1 '''Supplemental oxygen''' | ** 1.1 '''Supplemental oxygen''' |
Revision as of 16:56, 3 March 2018
Adult bronchiolitis Microchapters |
Differentiating Occupational lung disease from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Adult bronchiolitis medical therapy On the Web |
American Roentgen Ray Society Images of Adult bronchiolitis medical therapy |
|
Risk calculators and risk factors for Adult bronchiolitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
The optimal medical therapy for adult bronchiolitis is unknown. Therapy is mainly the cessation of exposure to irritant agent. Bronchiolitis is treated based on severity, however, the disease is progressive and inevitably, leads to respiratory failure. Therefore, supportive therapy includes supplemental oxygen, bronchodilators, cough suppressant, anti-reflux therapy, antibiotic macrolides, immunosuppressants and glucocorticoids. Bronchodilators and glucocorticoids have been heavily criticized in their role of improving symptoms, and are reserved only in those who show clinical improvement.
Medical Therapy
- Therapy is mainly the cessation of exposure to irritant agent.
- Bronchiolitis is treated based on severity, however, the disease is progressive and inevitably, leads to respiratory failure.
- Therefore, supportive therapy includes supplemental oxygen, bronchodilators, cough suppressant, anti-reflux therapy, antibiotic macrolides, immunosuppressants and glucocorticoids.
- Bronchodilators and glucocorticoids have been heavily criticized in their role of improving symptoms, and are reserved only in those who show clinical improvement.
Adult bronchiolitis
- 1 Stage 1 - Respiratory compromise
- 1.1 Supplemental oxygen
- 1.1.1 Adult
- Preferred regimen (1): maintain oxygen saturation at higher than 90% for 24 hours on standard flow rate
- Preferred regimen (2): maintain oxygen saturation at higher than 90% for 20 hours on high flow humidified oxygen
- Preferred regimen (3): maintain oxygen saturation at higher than 90% for 24 hours using Heliox (20 - 30% oxygen and 70 - 80% helium)
- 1.1.1 Adult
- 1.2 Antibiotic macrolide
- 1.1.2 Adult
- Preferred regimen (1): Erythromycin 200 - 600mg PO per day
- Preferred regimen (2): Clarithromycin 250 - 500mg PO per day
- 1.1.3 Bronchiolitis obliterans syndrome
- Preferred regimen (1): Azithromycin 250 mg daily for 5 days followed by 250 mg 3 times a week
- 1.1.2 Adult
- 1.1 Supplemental oxygen
References
- ↑ Azuma A, Kudoh S (March 2005). "Securing the safety and efficacy of macrolide therapy for chronic small airway diseases". Intern. Med. 44 (3): 167–8. PMID 15805698.
- ↑ Parambil JG, Yi ES, Ryu JH (April 2009). "Obstructive bronchiolar disease identified by CT in the non-transplant population: analysis of 29 consecutive cases". Respirology. 14 (3): 443–8. doi:10.1111/j.1440-1843.2008.01445.x. PMID 19210653.
- ↑ Akpinar-Elci M, Travis WD, Lynch DA, Kreiss K (August 2004). "Bronchiolitis obliterans syndrome in popcorn production plant workers". Eur. Respir. J. 24 (2): 298–302. PMID 15332401.